| abstract |
Disclosed herein are methods for preventing, suppressing or ameliorating complications associated with cardiopulmonary bypass surgery through the use of thrombin receptor antagonist compounds. Among the above thrombin receptor antagonist compounds, the compounds of formula (I), formula (II) and formula (III) described herein are useful in these methods. Examples of such thrombin receptor antagonists include the following formula (I), formula (II) and formula (III). |